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Abstract: Cervical cancer is the second most common cancer of women worldwide and is 
the first cancer shown to be entirely induced by a virus, the human papillomavirus (HPV, 
major oncogenic genotypes HPV-16 and -18). Two recently developed prophylactic 
cervical cancer vaccines, using virus-like particles (VLP) technology, have the potential to 
prevent a large proportion of cervical cancer associated with HPV infection and to ensure 
long-term protection. However, prophylactic HPV vaccines do not have therapeutic effects 
against pre-existing HPV infections and do not prevent their progression to HPV-associated 
malignancy. In animal models, therapeutic vaccines for persisting HPV infection can 
eliminate transplantable tumors expressing HPV antigens, but are of limited efficacy in 
inducing rejection of skin grafts expressing the same antigens. In humans, clinical trials 
have reported successful immunotherapy of HPV lesions, providing hope and further 
interest. This review discusses possible new approaches to immunotherapy for HPV 
associated cancer, based on recent advances in our knowledge of the immunobiology of 
HPV infection, of epithelial immunology and of immunoregulation, with a brief overview 
on previous and current HPV vaccine clinical trials. 
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1. Introduction  
Cervical cancer is the first cancer recognized by the World Health Organization (WHO) to be 100% 
attributable to an infection. Other cancers that are attributable to HPV infection include cancers of  
the vulva, vagina, anus and penis. The HPV family also includes the causative agents of genital and 
skin warts. 
Immunobiology of HPV & Epidemiology  
Papillomaviruses are non-enveloped, double-stranded DNA viruses that infect the epithelium. Their 
genome encodes six non-structural proteins [Early 1 (E1), E2, E4–E7] and two structural proteins 
[Late 1 (L1) and L2]. Early proteins control the DNA-replication machinery of the infected cells by 
altering cell cycling and promoting viral genome replication, while late proteins, which form the 
capsid, are involved in the packaging of the virion [1]. 
The epithelium is a multilayered stratified tissue with a vertical organization correlated with 
keratinocyte differentiation and maturation: at the basement are dividing stem cells in contact with the 
dermis, followed by a layer of non-dividing keratinocytes, a squamous layer and finally, the mature 
squamous layer that is in contact with the external environment [2]. 
More than 100 HPV types have been identified, almost 40 of which infect the anogenital region. 
Genital HPV are divided into low- (i.e., types -6 and -11, associated with anogenital warts and mild 
dysplasia), intermediate- and high-risk categories (i.e., types -16, -18, -31, and -45, associated with 
high-grade dysplasia and anogenital cancers, such as cervical and anal carcinoma), depending on their 
association with cancer. The two most studied HPV are HPV-16 and -18, which contribute to almost  
70% of all cervical cancers. Three novel papillomaviruses, HPV-109 from an SCC, HPV-112 from a 
condyloma and HPV-114 from a cervical lesion, have been identified recently, with more HPV types 
still to be characterized in HPV-associated lesions [3].  
Genital papillomaviruses infiltrate epithelial lesions and infect cells of mucosal or squamous epithelia. 
As long as the infected epithelial cells are dividing, the virus will remain in its free (non-integrated) 
episomal form and replicate using the cellular DNA-replication machinery. At an early stage, the 
proteins E1 and E2 delay cell differentiation and promote cell replication and thus viral genome 
amplification. When epithelial cells mature and stop dividing, virion particles are formed and mature 
virions can be released from the epithelial cells. HPV-induced genital lesions often regress 
spontaneously within a year, but may persist in about 2% of cases for five years or more, with the 
histological hallmarks of CIN1 (cervical intraepithelial neoplasia). As the infection persists, these 
lesions can progress to CIN2 and CIN3. In one-third of cases, CIN3 lesions can develop into cancer. In 
cervical cancer lesions, the HPV DNA is mostly found integrated in the cellular genome [1].  
2. Immune System and HPV  
2.1. Role of the Immune System: Lessons from Immunocompromised Patients  
The incidence of some cancers is higher in immunocompromised patients. Immune suppression 
after organ transplantation is connected with increased risk of virus-associated cancers [4] including 
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HPV-associated cancers. For example, individuals with acquired immunodeficiency syndrome (AIDS) 
are at higher risk of HPV-associated cancers [5,6], consistent with the higher prevalence and more 
frequent persistence of HPV infections [7,8]. HPV-induced anal cancer in an HIV-positive population 
is most commonly associated with HPV-16 infection (75%) followed by HPV-18 (less than 10%). The 
prevalence of HPV in anal cancer is higher in women (90%) than in men (75%) [8]. 
Immunosuppression is often reflected in low CD4 T-cell numbers in individuals with HIV. In a 
recent study, data from individuals diagnosed with AIDS over twenty five years were collected and 
analysed for HPV–associated cancers. A low CD4 T-cell count measured at AIDS onset was 
associated with significantly increased risks of HPV-associated invasive cancers, including anal 
cancers among men and vaginal or vulvar cancers among women. In the same study, in situ cervical 
cancer risk was lower and invasive cervical cancer risk was higher in patients with AIDS, although 
differences were not statistically significant due to the lack of sufficient data for cervical cancer 
patients. In contrast to the high risk of anal and other HPV-associated cancers, the risk of invasive 
oropharyngeal cancer was only moderately elevated among persons with HIV when compared with the 
general population. This modest increase in risk may reflect the fact that only a few oropharyngeal 
cancers (about 30% of tonsillar epithelial cancers) are caused by HPV [8] or the longer time for 
progression of HPV infection in the mouth to cancer. Although providing a link between immune 
suppression (low CD4 T-cell count measured at AIDS onset) and increased incidence of HPV-associated 
cancers, the above-mentioned study did not consider HIV burden at the time of AIDS onset, which is 
another marker of the degree of immunosuppression and may be important in the natural history of 
HPV-associated cancers [8]. The evidence discussed above thus suggests a direct role for the immune 
system in the control of infection by HPV. 
2.2. Role of the Immune System: Spontaneous Immune Responses to HPV-Associated Cancer  
Most HPV infections are transient, becoming undetectable within the first two years in 
immunocompetent individuals. While the spontaneous regression of latent HPV infection is difficult to 
assess due to the sensitivity of assays and challenge in discriminating between positive and negative 
samples (discussed in 3.2), lesions have been shown to often regress spontaneously in young  
women [9,10]. It has also been reported that a few percentage of CIN2-3 lesions can regress 
spontaneously to CIN1 or less [11]. However, different spontaneous regression rates exist depending 
upon the type of HPV, with high-risk HPV-16 and phylogenetically linked HPV being less 
spontaneously cleared than low-risk HPV [12,13]. The spontaneous regression of HPV lesions is 
associated with the local presence of a range of adaptive immune cells (B cells and CD8+, CD4+ and 
CD25+ T cells) [11,14]. Data from immuno-deficient or -competent individuals suggest that the 
immune system is highly involved in the success or failure of spontaneous HPV clearance. This also 
implies that boosting such immune responses by therapeutic vaccine could enhance clearance rates. In 
the next paragraphs, we will discuss the role of immune cells during HPV infection. 
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2.3. Role of Immune Responses and Cell Types with Regards to HPV  
2.3.1. Humoral Immunity 
Adaptive immune responses to HPV infection include humoral (B cell, antibody) responses specific 
for viral structural (L protein) or non-structural (E protein) antigens. The L1 major structural protein of 
HPV assembles into particles or capsids indistinguishable from native virions. Although papillomavirus 
capsids have been shown to be quite immunogenic when injected into animals [15,16], the natural 
antibody response to L1 is weak, probably because the L1 protein is expressed in the squamous 
epithelium, a site that may not allow efficient immune activation. Nevertheless, those capsids are a 
major tool for the study of serological responses to HPV. Most studies have examined the prevalence 
of antibodies to HPV capsids by ELISA [17] and compared their findings with the presence of HPV 
DNA using PCR-based testing and neoplasia or genital warts by Papanicolaou (Pap) screening.  
There is considerable variability in the timing of the HPV-specific antibody response in relation to 
HPV infection. Nevertheless, serum IgG antibodies, which have a neutralizing potential, develop in 
response to infection in more than 50% of women. The kinetics of antibody development are slow (6 to 
12 months), and the peak titres are low, but antibodies can persist for decades unless HPV-associated 
lesions resolve. Secretory IgA antibodies can also be detected in the cervical secretions of HPV-positive 
women with a similar time course of appearance to IgG antibodies, but with a shorter persistence  
time [18]. However, studies have also suggested that antibodies to HPV may persist for years after the 
disappearance of measurable disease, making it difficult to discriminate whether antibodies are due to 
past or persistent infection [19,20]. Antibodies to non-structural proteins after natural infection are rare 
or nonexistent. However, relative to the presence of HPV DNA at the initial stages of infection, 
antibodies against HPV-16 and -18 non-structural E2, E6 and E7 proteins were detected in only half of 
patients tested [21]. A stronger correlation has been demonstrated between E7 antibodies and advanced 
cervical cancer [22-24]. 
HPV antibody assays are problematic because the levels of antibody are low, the threshold for 
positivity is difficult to define, and correct antigens (with the exception of L1 VLP) are not well 
characterized. Spontaneous clearance of HPV infection occurs in the majority of patients, and has been 
largely attributed to the cellular immune response rather than the humoral immune response, as further 
described below and in Figure 1.  
2.3.2. Cellular Responses  
CD4+ and CD8+ T-cells- High-risk HPV infections can progress to high-grade CIN due to 
impaired T-cell immunity (Fig 1). HPV early proteins are required early in viral infection and therefore 
may serve as a useful vaccine target in HPV-infected individuals, aimed at prevention or therapy of 
premalignant lesions. Since the E6 and E7 oncoproteins of HPV viruses are expressed in precancerous 
lesions, such proteins might be potential tumor-specific targets for immunotherapy. The E5 protein of 
HPV-16 is known to downregulate MHC class I expression on infected cells and could be targeted to 
allow re-expression of MHC and recognition of infected cells by CD8+ T cells [25].  
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Figure 1. Proposed model for the association between HPV-16-specific T-cell immunity 
and the development of disease (adapted from [26]). Thick arrows represent the fate of the 
majority of HPV-16-infected individuals, in contrast to thin arrows that represent the fate 
of the minority of HPV-16-infected individuals. Dotted arrow indicates that some cases of 
spontaneous regression can occur, probably by the induction of T-cells and/or cells from 
the microenvironment, which leads to the destruction of infected tissues or tumor mass. 
Dashed box represents the immunological mechanism that is likely involved. 
 
There are several studies providing information about CD4+ and CD8+ cytotoxic T-cell responses 
to HPV-16 early proteins [27]. Using fusion proteins, panels of overlapping peptides, virus-like 
particles or tetramer technology, CD4+ T cell responses to HPV-16 E2 [28], E4 [29,30], E5 [31],  
E6 [29,32] and E7 [33] have been demonstrated in both patient and healthy control populations 
without clear consequences for resolution of HPV infection. HPV-16 E2-, E6- and E7-specific CTLs 
can also be detected in patients with previous or ongoing HPV infections [34,35]. Moreover, T-cells 
can also be found that recognize late proteins, such as HPV-16 L1 [36], although responses to L1 are 
not thought to be important in viral clearance once HPV infections are established. Overall, HPV 
specific T-cells detected in patients with HPV infection are not anergic but functionally active, as has 
been demonstrated using a variety of restimulation protocols such as gamma-interferon (IFN-) release 
by ELISPOT and chromium 51 release by cytotoxic assay [34,35]. To highlight this, a recent study 
described the first clinical success for therapeutic vaccination of vulvar intraepithelial neoplasia 
(VIN)3 patients with a vaccine which comprised HPV-16 E6 and E7 synthetic long overlapping 
peptides (HPV16 SLP). This vaccine induced a CD4+ and CD8+ T cell response with IFN- production 
and led to a durable and complete regression of HPV-induced lesions in half of the patients [37]. 
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NKT- Natural killer T (NKT) cells are a heterogeneous group of T cells that recognize self or 
microbial lipid antigens presented by CD1d molecules. CD1d is a major histocompatibility complex 
(MHC) I-like glycoprotein present on the surface of not only antigen presenting cells but also intestinal 
epithelial cells, keratinocytes and reproductive tract epithelial cells [38].  
The most widely studied ligand of NKT cells is -galactosylceramide (-GalCer) [38]. A recent 
study has used -GalCer as an adjuvant with DNA vaccination against HPV-16 oncoprotein E7 to 
generate high numbers of E7-specific CD8+ T-cells protective against the transplantable TC-1 (HPV-16+) 
tumour model in mice [39]. Another NKT ligand, -galactosylceramide, has also been shown to be 
protective against the same tumour [40]. These data thus highlight the potential of NKT ligands as 
therapeutic agents for HPV-associated cancers.  
MHC cell surface downregulation is one of the mechanisms employed by a variety of tumours to 
evade immune detection. Cell surface CD1d, a MHC-Ib molecule, is down-regulated in HPV-related 
lesions and in HPV-negative cervical cancer cell lines stably transfected with HPV-6 E5 and HPV-16 
E5, thus linking decreased CD1d expression in the presence of HPV infection with evasion of NKT 
cells [41]. On the other hand, studies in a mouse model expressing HPV-16 E7 oncoprotein in 
keratinocytes have shown that IFN- produced by invariant NKT cells in the skin provides protection 
against E7 transgenic skin graft rejection [42]. A small study on a North Indian population has also 
shown an association of the IFN- +874 polymorphism with an increased risk of cervical cancer in 
patients at stages III + IV. However, this study did not include all clustered polymorphism sites of 
IFN- and was not free from selection bias [43].  
Based on the literature, NKT cells may play two different roles, depending on the type of HPV 
lesions. In established HPV-associated cancerous lesions, activation of NKT cells may provide 
therapeutic value, while inhibition of NKT cell activity or recruitment in precancerous lesions may 
allow a protective immune response. 
Treg- Regulatory T cells (Treg) are CD25hi Foxp3+ CD4+ T cells that have been involved in the 
failure of the immune system to control the development of numerous cancers both in humans and in 
mice [44,45]. Therefore, a high frequency of Treg in human HPV-associated cancer could counteract 
the host immune response and thus influence therapeutic strategies. 
Indeed, human, high-grade CIN lesions (CIN3) and cervical carcinomas have been shown to 
contain higher numbers of infiltrating lymphocytes and FoxP3+ Treg compared to colon carcinomas, 
skin melanomas, and bronchial carcinomas [46-48]. Moreover, mucosal enrichment of Treg cells was 
associated with a diminished cellular immunity in the cervical mucosa, and both seemed to contribute 
to the development of high-grade CIN 2 and 3 lesions [49].  
Notably, Treg may also be induced by therapeutic vaccines. In a study comparing patient groups 
with small or large HPV-16-positive vulvar lesions, larger lesions were found to contain higher 
frequencies of vaccine-induced HPV-16-specific Foxp3+ Treg cells, correlating with early treatment 
failure [50]. A similar result has also been observed in a mouse model [51]. Moreover, it has been 
shown that the process of repeat vaccinations can increase the presence of regulatory T cells [52]. This 
suggests that the combination of therapeutic vaccination with the depletion of Treg or at least the 
abrogation of their suppression should improve cancer therapy. 
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The in vivo depletion of Treg has already proved to be efficient in allowing the rejection of 
established tumours in mice and humans [53-58]. In an animal model of HPV-associated cancer, the 
therapeutic depletion or inactivation of Treg has been shown to induce a strong intratumoral invasion 
of CD8+ T cells and complete eradication of HPV-16 E6/E7-expressing tumor cells in 70% of treated 
animals [48]. Moreover, combining T-cell therapeutic vaccination and Treg depletion can lead to the 
complete eradication of HPV-expressing tumors in mice [59]. In patients with condylomata acuminata, 
Treg depletion using cyclophosphamide ameliorates the immune milieu of the lesion site, leading to 
the elimination of remnant viruses and helps prevent recurrence after laser therapy [60]. As a 
consequence, the role of Treg should be scrutinized within HPV vaccination strategies. The temporary 
removal of Treg from patients should be considered as a means to improve the benefits of therapeutic 
vaccination targeting HPV-associated lesions. 
2.3.3. Myeloid Cells  
Macrophages. Macrophages are one of the three types of phagocytes in the immune system and are 
distributed widely in the body tissues, where they play a critical part in innate immunity. Macrophages 
are found in many areas of lymph nodes, particularly in the marginal sinus and in the medullary cords. 
Here they can actively phagocytose pathogens and antigens, and so prevent them from entering the 
blood. Activated macrophages undergo changes that greatly increase their antigen-presenting function 
and anti-pathogen effectiveness, and amplify the immune response.  
Regarding their role in HPV infection, studies in women infected with HPV have shown a positive 
correlation between lesion grade, the number of infiltrating macrophages and IL-10 expression by 
these cells [61-63]. However, macrophages have also been reported to react against E6 and E7. 
Macrophages can kill HPV-16 E6 but not E7-expressing tumor cells through tumor necrosis factor 
(TNF)- and nitric oxide (NO)-dependent mechanisms [64,65]. It has also been shown that HPV-16 
E7, but not E6, NIH-3T3 human cells were susceptible to activated macrophages, and that the ability 
of E7 to cause transformation was required to induce susceptibility of infected cells to activated 
macrophages [66]. Thus, the role of macrophages in HPV infection is still unclear. 
The tumor microenvironment has been shown to influence tumor immune privilege, and this has 
become a new field of research in tumor immunology. Macrophages are enriched in several types of 
human cancer, including breast, ovarian, non-small cell lung cancer, and Hodgkin’s lymphoma, and 
their presence correlates with a poor clinical outcome. Tumor-associated macrophages (TAM) have 
been therefore identified as regulators of tumor development. As an example, TAM have been shown 
to play a major role in colorectal cancer by recruiting Treg to the tumor mass, thus favouring  
an immunosuppressive microenvironment that leads to tumor growth [67]. TAM can also act by 
suppressing tumor-infiltrating T-cells through several mechanisms, as seen for example under  
hypoxic conditions [68]. TAM have been shown to be recruited in situ through the macrophage  
colony-stimulating factor (CSF-1), as its over-expression correlates with poor prognosis in breast 
cancer [69]. Therefore, macrophages can have opposing roles within the immune response against 
tumorigenesis and infection, and their role in high risk HPV infection is yet to be investigated. 
Myeloid derived suppressor cells. Myeloid derived suppressor cells (MDSC) are a heterogeneous 
population of cells that have been associated with cancer, inflammation and infection, and been shown 
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to suppress T-cell responses. A regulatory role for MDSC, as well as regulatory T cells, has been 
highlighted in animal models using transplantable tumour cells expressing the E7 protein, TC-1. One 
recent study found reduced MDSC and Treg numbers in both the spleen and transplantable tumour 
itself through the use of a tri-therapy combination HPV vaccine, leading to the restoration of a potent 
E7-specific CD8 T-cell response and the control of tumour growth [70]. Another study using the same 
tumour line, but E7 DNA vaccine instead, showed a reduction in MDSC numbers but not Treg cells in 
the tumour microenvironment, which was sufficient to control tumour growth. Adding Imiquimod to 
the E7 DNA vaccine further reduced MSDC numbers and activated of a CD8 response, improving the 
anti-tumour response mediated by E7-specific CD8 T cells, macrophages and NK1.1+ cells [71]. 
Despite no demonstrated association with HPV-associated cancers in humans, MDSC have been 
observed with increased prevalence in the peripheral blood and tumor microenvironment of patients 
with head and neck squamous cell carcinomas [72] and pancreatic cancer [73]. By further elucidating 
the mechanisms of MDSC recruitment and maintenance in the tumor environment in mice and 
humans, new vaccine strategies may be developed to reverse the suppression of anti-tumour immunity. 
Mast cells. Mast cells (MC) are localized at body sites that interface with the environment, such as the 
skin and mucous membranes, which are also the site of HPV infection. Mast cells are highly specialized 
innate immune effector cells that contain secretory granules in which large amounts of proteases are 
stored in complexes with serglycin proteoglycans [74]. The presence of mast cells along with other 
immune cells has been shown in CIN2/3 lesions [75], though their main role in HPV pathogenesis is 
difficult to determine due to their “tunable” function. They can indeed act as pro-inflammatory cells 
through the recruitment of innate and adaptive immune cells, or as immuno-suppressive cells through 
the production of the immunosuppressive cytokine IL-10 [76]. Burns [77], tape stripping, tumors [78], 
allergy, parasitic and virus (HIV) infections have each been shown to recruit mast cells into the skin.  
A major point linking mast cells to cancer is that mast cells accumulate in the stroma surrounding 
certain tumors, especially mammary adenocarcinoma, where they have been shown to synthesize  
and secrete potent angiogenic cytokines, such as vascular endothelial growth factor (VEGF). These 
molecules facilitate tumor vascularisation by a direct angiogenic effect and by stimulating the stroma 
and inflammatory cells of the tumor microenvironment [79,80]. In relation to their ‘tunable’ function, 
mast cells in the local environment can also be detrimental for the tumours themselves, secreting 
immune mediators such as IL-1, IL-4, IL-5, IL-6 and TNF- that can induce apoptosis of tumor cells 
and recruit inflammatory cells [80]. As is the case for macrophages, the role of mast cells in the 
immune response to HPV infection is still largely unknown.  
Dendritic cells. Dendritic cells (DC) are potent antigen-presenting cells (APC) that play a 
fundamental role in the induction and regulation of innate and adaptive immune responses  
against microbial pathogens. DC in human and mice can be broadly categorised into two major 
populations: plasmacytoid DC (pDC) and conventional DC (cDC), which can be further divided into 
migratory DC (Langerhans cells (LC) and interstitial DC) residing in peripheral tissues and lymphoid 
tissue-resident DC.  
In humans, pDC are present in cervical cancer lesions, primarily in the stroma underlying the tumor 
rather than the dysplastic epithelium, and produce the anti-viral cytokine, IFN-, in response to HPV 
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VLP [81,82]. These studies suggest pDC play an important function in the natural immune response 
against HPV, although their role in cervical cancer development remains unclear. 
Epithelial LC are the model migratory DC, initiating immune responses to infecting pathogens by 
capturing Ag and delivering it to the T cell areas of the draining lymph nodes. Several studies have 
documented reduced numbers of LC in human HPV-associated cervical lesions [83-86], suggesting the 
depletion of epithelial LC during HPV infection may lead to prolonged infection and possibly 
oncogenesis. Furthermore, LC incubated with HPV VLP fail to up-regulate surface activation markers 
or initiate a HPV-specific immune response, suggesting that HPV avoids immune recognition through 
poor stimulation of LC [87, 88]. 
A unique population of interstitial DC has been recently defined in the cervical stroma, with 
elevated numbers of these cells in human cervical cancer relative to normal cervix. This stromal DC 
subset is distinct from LC and expresses immuno-suppressive factors IL-10, TGF- and indoleamine 
2,3-dioxygenase (IDO) [63,75,89]. However, there are several additional mechanisms by which 
stromal inflammatory cells could contribute to tumor escape. For example, PD-L1 (B7-H1), expressed 
on multiple cell types including APC, and PD-L2 (B7-DC), selectively expressed by DC and macrophages, 
are both expressed in human cervical cancers [90]. 
DC are regarded as the master regulators (chef d’orchestre) of the immune response. They have 
been utilized in numerous vaccination protocols to boost antigen presentation and T-cell costimulation 
and thus, augment antigen-specific T-cell responses. However, their multiplicity of phenotypes and 
functions make it difficult to know which population(s) of APC should be targeted. 
3. Prophylactic HPV Vaccines 
3.1. VLP  
Virus-like particles (VLP) are a useful tool for development of vaccines and are often used in 
studies to identify viral assembly proteins. They resemble the native virus immunologically but are 
non infectious as they don’t contain viral genetic material. Two prophylactic HPV vaccines (Cervarix 
and Gardasil) that are currently in use are based on the L1 major capsid protein. The HPV L1 open 
reading frame translates a 55-kD protein that efficiently self assembles into viral capsomeres and 
empty capsids, when expressed in eukaryotic cells [91]. In papillomavirus VLP vaccine production, 
the L1 gene is cloned, and amplified using primers specific for the L1 gene. The amplified L1 segment 
is then inserted into an appropriate intermediate expression vector and used to produce recombinant L1 
yeast [92], vaccinia [91] or baculovirus [93]. These are then purified and used to express L1 in 
eukaryotic cells [91]. The L1 self assembles to form VLP and does not require L2 or other non 
structural proteins. The resulting VLPs are immunologically similar to the native viron. These are then 
finally combined with alum-based adjuvants to make the basis for prophylactic vaccines. 
Cervarix & Gardasil: 5-years overview. Cervarix™ is a bivalent vaccine manufactured by Glaxo- 
SmithKline that incorporates two HPV types (HPV-16, HPV-18) responsible for 70% of cervical 
cancers. Gardasil™, manufactured by Merck, is a quadrivalent vaccine that additionally incorporates 
HPV-6 and HPV-11. HPV-6 and -11 cause an estimated 75-90% of genital warts cases. 
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Cervarix: HPV-16 and -18 VLP are produced in Trichoplusia ni Rix4446 cell substrate using a 
baculovirus expression vector system and formulated with the adjuvant system ASO4 that is 
comprised of 3-O-desacyl-4 monophosphoryl lipid A (MPL) and aluminum hydroxide salt. The 
vaccine is administrated intramuscularly in three dose schedule - months 0, 1 and 6.  
Gardasil: HPV -6, -11, -16 and -18 VLP are produced in yeast Saccharomyces cerevisiae and 
formulated with adjuvant aluminum hydroxyphospate sulfate. The vaccine is administrated 
intramuscularly in three dose schedule - months 0, 2 and 6 [79]. 
These prophylactic vaccines are licensed for use to prevent HPV infection and anogenital cancers in 
females and males aged 9–45 in many countries, and are administrated to teenage girls as a part of the 
routine immunization schedule in some. In addition, the quadrivalent vaccine is licensed for use to 
prevent genital warts in some developed countries. The use of these vaccines in developing countries is 
limited by cost-related issues. Thus, provision of prophylactic HPV vaccines to a wider population 
through development of biosimilar vaccines is under consideration in developing countries.  
As long as women are sexually active they remain at risk of cervical HPV infection. Therefore, it is 
essential that HPV vaccines provide long-lasting protection. Clinical efficacy has been observed up to 
6.4 years for the bivalent vaccine [94] and up to 8.5 years for the quadrivalent vaccine [95,96]. Since 
most HPV infections are silent, it will be many years before we know for certain about the duration of 
protection and efficacy provided by HPV vaccines. A mathematical modeling study based on three 
different statistical models and follow-up data from more than 300 vaccinated women, has predicted 
that anti-HPV-16 and -18 antibody levels with the bivalent vaccine will persists for at least 20 years [94]. 
In addition to showing 100% efficacy in preventing pre-cancerous lesions, HPV vaccines also provide 
some cross-protection against other HPV subtypes (60% and 78% efficacy in preventing incident 
infections secondary to subtypes HPV-31 and -45 respectively) (reviewed in [97]). 
Based on phase III clinical trial results [98], the Advisory Committee on Immunization Practices 
(ACIP) states that women should be advised that the vaccine will not have any therapeutic effect on 
existing infection or disease and they should continue to receive routine cervical cancer screening [99]. 
3.2. Who and When To Vaccinate 
To allow meaningful approaches to vaccine development, both prophylactic and therapeutic, it is 
important to identify the age at which the population is infected, the extent of exposure to human 
papillomavirus within the general population, how long the infection persists and if the immune 
response to HPV is consistent throughout life. One of the key questions also remains to understand the 
first transmission of the virus and whether sexual transmission is the only route for high-risk HPV. 
Perinatal transmission. The detection of human papillomaviruses including HPV-16 and -18 in 
neonates have been described in about 50% of cases where the mother is infected at the time of delivery. 
In two early studies, HPV-16 and -18 DNA were detected in buccal and genital swabs in more than  
70% of infants at 24 hours post delivery and persisted in more than 80% of contaminated infants at 6 
weeks through to 6 months of age [100,101]. Other studies also provide evidence that HPV-DNA 
could be found within the nasopharyngeal aspirate fluids and oral cavity of neonates [101-104].  
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The mode of delivery at birth, vaginal versus caesarean, may play a role, as a significantly higher 
rate of HPV-16/-18 infection was found at birth when infants were delivered vaginally [105]. Ten 
years later, two studies analysed the type-specific HPV concordance in infected mothers, the placenta 
and the newborn or the infected mother and the cord blood in about 60 to 70 cases, but they only  
found a small incidence of placental infection, and an even smaller incidence of transplacental 
transmission [106,107]. One of the largest studies of newborn HPV infections to date, and the first  
to use sequencing methods to evaluate if a vertical transmission of HPV from infected parents does 
occur, showed a lack of concordance for the HPV type between the mother and child or the father and 
child [108]. These data support the rarity of perinatal high-risk HPV transmission and suggest other 
potential sources of exposure or contamination. Altogether, there is no obvious evidence for the 
transmission of high-risk HPV-16 and -18 to the genital tract at birth. Although common to detect 
HPV-16/-18 DNA in the oral cavity of newborns, it does not persist nor replicate, and the only disease 
attributable to vertical transmission is for recurrent respiratory papillomatosis (RRP), which is caused 
by HPV types -6 and -11 with a 1:1000 live birth event [95].  
Adolescence. If the only possible method of genital HPV infection is sexual transmission,  
non-infected individuals could be found within virgin girls and young women. On the other hand, if 
nonsexual transmission can occur, some virgins might have genital HPV-specific antibodies, and this 
would increase the cut-off and reduce test sensitivity if virgin females were used to provide a reference 
standard for antibody testing. Therefore, it would be informative to determine the antibody status in 
pre-pubertal children. Here, the results from different studies are controversial, as it is crucial to define 
the antibody detection methodology, and what would be a “positive” and a “negative” control for an assay. 
One large study in Edinburgh examined more than 1,000 serum samples from a cohort of 11–13 
year-old virgin school girls for the presence of antibodies to HPV-1, -2, and -16 VLP. The study 
reported that 7% of study subjects had antibodies to HPV-16 VLP, 52% to HPV-1 and 38% to HPV-2. 
In contrast, a Swedish study showed that virgin teenage girls were not seropositive in an HPV-16 
VLP-based ELISA, while 14% of early sexually experienced girls were detected HPV seropositive and 
positive for HPV-16 DNA, leading to a conclusion that non-sexually transmitted infections are rare or 
nonexistent among adolescent girls [109]. Another study conducted in South Africa with children aged 
between 1 and 12 years found that 4.5% of sera tested were positive for antibodies to HPV-16, with a 
prevalence decreasing with age. This could indicate vertical transmission of HPV infection, but HPV 
DNA from children and parents were not tested to confirm or invalidate this conclusion [110]  
Altogether these data show the difficulty in defining an HPV antibody positive from a negative 
serum. This makes interpretation of data on early HPV infection problematic. However, the balance of 
evidence suggests that there are only very few, if any, HPV infections caught before the onset of 
sexual activity. 
Adult age. The prevalence of high risk HPV in the general population is well known. Women 
acquire HPV infection soon after onset of sexual activity [111] and more than 50% of adult women  
are HPV-16 seropositive, a percentage increasing with the number of partners and sexual  
behaviour. Moreover, studies on older women (>65 years old) indicate an impairment in host 
immunologic responses, with decreased lymphoproliferative responses associated with persistent HPV 
infection [112,113]. Taken together, the available data lead to the conclusion that the HPV 
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prophylactic vaccines currently available should ideally be administered before the onset of sexual 
activity, prior to exposure to HPV infection. 
Men. Cancers of the penis, anus, and oropharynx in males can be due to high risk HPV infection, 
although less than 25% of HPV-related cancers occur in males. However, HPV infections and related 
non-malignant diseases are common in males [114, 115]. The rate of genital HPV infection in males, 
and the probability that a sexually active male will acquire a new genital HPV infection, are equivalent 
to the rates in females. Increasing numbers of sexual partners and preference for male partners are each 
associated with an elevated risk of HPV acquisition [116]. However, there are differences between the 
sexes in the immune response to genital HPV infection: seroprevalence in men is lower than in women 
(7.9%, vs. 17.9%, respectively), with lower titres of antibodies [114,117]. 
A recent study enrolled more than 4,000 healthy boys and men between 16 to 26 years of age  
from 18 countries in a randomized, placebo-controlled, double-blind trial, and demonstrated that the 
quadrivalent HPV vaccine used as a prophylactic vaccination can reduce the incidence of some  
HPV-related infections [118]. There are two potential advantages to vaccinating males: the first is the 
direct benefit for those immunised and the second, indirect but not less important, is that this can 
improve protection of females, by reducing virus transmission.  
Despite the success of preventive HPV vaccines, such vaccines are unlikely to reduce the global 
burden of HPV-associated cancers in the next few years due to their high cost and limited availability 
in developing countries, where there is a high incidence of cervical cancer. Moreover, existing 
preventive HPV vaccines do not generate therapeutic effects. Therefore, it is worthwhile to consider 
alternative strategies to treat HPV-associated premalignancy and malignancy.  
3.3. When To Vaccinate with a Therapeutic Vaccine? The Sooner, the Better… 
Thymic involution with age. With age, the immune system undergoes dramatic changes. From fetal 
to neonatal periods, naïve T-cells are extensively produced and migrate from the thymus to secondary 
lymphoid organs in the periphery, where they accumulate and display a broad and polyclonal 
repertoire. From youth to adulthood, thymic export is balanced by cell death at the periphery, leading 
to an equilibrium in the apparent quantity of cells. With age, the thymus involutes and numbers of 
newly generated naïve T-cells gradually fall. Together with this thymic involution, an immune decline, 
termed immunosenescence, progressively alters B- and T-cell functions. In counterpart, an accumulation 
of antigen-experienced peripheral T-cells is observed, both in the CD4+ and CD8+ compartments, 
likely due to an accumulation of memory responses following antigen activation and from homeostatic 
proliferation to maintain T-cell levels [119]. It is reported that the TCR repertoire of elderly persons 
(age > 75 years) is severely contracted. In fact, the TCR diversity of elderly persons in both the CD4+ 
and CD8+ compartments is at least 100-fold less diverse than the TCR diversity in younger individuals 
(age 20–35) [119,120]. As a consequence, it seems that a therapeutic vaccine should be administered 
early enough during adulthood to elicit the maximum efficiency. 
Critical window of time. Another fact arguing in favour of an early therapeutic vaccination comes 
from the analysis of vaccination strategies against transplantable tumours in mice. Indeed, it has been 
shown in mice that a vaccine is more potent and will generate a strong anti-cancer effector response 
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when it is administered within a certain time frame [121]. In humans, in HPV-16-positive vulvar 
lesions, it has been shown that patients with a smaller lesion and a shorter history of disease were 
significantly more responsive to therapeutic vaccines, compared to patients with larger lesions and 
longer history of disease [50]. This suggests that the earlier a therapeutic vaccine is administered after 
the appearance of cancer, the improved probability of a positive clinical response. 
The side effects: Treg cells. We have previously discussed in Section 2 the deleterious role of  
Treg in cancer. Moreover, it has been described in mice that, at the very time of tumour emergence, 
self-specific Treg were activated early and briskly by self-antigens expressed by tumours, driving  
a secondary-type immune response in essence more rapid and efficient than the primary-type response 
of naive effector T-cells specific for tumour neoantigens [55]. This mechanism of ‘déjà vu’ explains  
an old paradigm of cancer immunology, that preventive immunization is more effective than 
therapeutic immunization.  
Therefore, here again, it seems that early vaccination after the detection of cancer might be the 
preferred option to promote a maximum anti-tumour response. In that case, an improved effort in the 
screening of cervical cancers or skin cancers induced by HPV infection is also a key in the success of 
immunotherapy for HPV-associated cancers. 
4. Therapeutic HPV Vaccines 
Current treatments for HPV-associated lesions rely primarily on excision or ablation of the infected 
lesion. Ablative therapies are effective when the disease is localized as in the case of CIN but the 
possibility of recurrence remains, as treatment does not always eradicate the underlying HPV 
infection. A successful immunotherapy might therefore be a preferred mode of treatment because it 
can target all HPV-associated lesions irrespective of their location. Ideally, it would also induce long-
lasting immunity, thus preventing recurrence.  
Therapeutic cancer vaccines are anticipated to treat an existing cancer by enhancing the naturally 
occurring immune response to the cancer. Unlike prophylactic vaccines, which protect against HPV 
infection by generating neutralizing antibodies, therapeutic vaccines would likely require induction of 
antigen-specific T-cells for clearance of HPV-associated lesions (reviewed in [122]). Most of the 
therapeutic vaccines developed to date for HPV-associated disease have failed at the clinical stage, 
despite promising results in preclinical animal models. One possible reason for failure is that these 
vaccines have generally been tested in advanced stage cancer patients, where the chances of their success 
are reasonably poor. Nevertheless, we have to mention here some of the recent and successful therapies 
against HPV-associated cancers, in HPV-16 associated vulval intraepithelial neoplasia [37,123] and in 
HPV-16 associated cervical cancer [124]. They will be further discussed in each section of this 
chapter. The therapeutic vaccine should also be directed against the right target. The capsid proteins 
L1 and L2 are no longer expressed after the integration of HPV DNA into the DNA human host cells, 
rendering them inappropriate as therapeutic targets. On the contrary, the two oncoproteins E6 and  
E7 are expressed throughout the viral life cycle and are required for continued tumor growth. The  
E6 oncoprotein degrades tumor suppressor p53 via direct binding to the ubiquitin ligase E6AP  
and contributes to tumorigenesis [125,126]. The E7 oncoprotein binds and induces proteasomal 
mediated degradation of the retinoblastoma family of proteins (pRB, p107 and p130), which are 
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required for processes such as cell cycle progression, DNA repair, apoptosis, senescence and 
differentiation [126, 127]. Hence, E6 and E7 oncoproteins appear to be good candidates for HPV 
vaccination strategies. However, the proteins E1 and E2 are expressed early in the progress of an HPV 
infection before the integration of the viral genome into the host DNA. E1 encodes for the helicase and 
E2 is a regulatory protein and they both have a role in viral replication. In line with our hypothesis that 
the vaccine should be delivered as soon as possible after infection by HPV (as discussed in Section 3.3), 
E1 and E2 may be the best targets for a therapeutic vaccine. Indeed, vaccination against E1 and E2 
have already been shown to induce protection in dogs [128] and rabbits [129]. In humans, E1 and E2 
have been reported to induce both natural and vaccine-induced T-cell responses in patients with 
persistent cervical neoplasia [130]. Together with a good target, HPV vaccines need to be delivered 
correctly. In the following sections, we will discuss various strategies as candidates for delivery of 
therapeutic HPV vaccines. 
4.1. Live Vector-Based Vaccines 
Live-vector based vaccines are highly efficient in delivering relevant antigens or DNA encoding 
antigens of interest. These vaccines have advantages including the possibility of choosing a desirable 
vector from a wide range of vectors to deliver antigens. Moreover, replication and spreading of live 
vectors in the host results in potent immune responses. However, using live vectors poses safety 
concerns in clinical applications. Additionally, neutralizing antibodies to the live vector, generated 
upon vaccination, may limit the efficiency of repeated immunizations with the same vector. The most 
common types of live vectors used for vaccinations are bacterial and viral vectors. 
4.1.1. Bacterial Vectors 
The two most promising bacterial vectors for therapeutic HPV vaccines are Listeria and 
Salmonella. Listeria is a gram-positive intracellular bacterium that occasionally causes disease in 
humans. Listeria monocytogenes (LM) has the ability to replicate in the cytosol of APCs after escaping 
phagosomal lysis by secreting a factor called listeriolysin O (LLO). This unique feature allows peptide 
antigens derived from LM to be processed and presented via both MHC class I and class II pathways, 
resulting in potent CD4+ and CD8+ T-cell-mediated immune responses.  
Preclinical models. Listeria-based vaccines targeting E7 have been shown to cause regression of 
solid implanted tumors in HPV-16 E6/E7 transgenic mice [131]. These vaccines can also inhibit the 
growth of thyroid tumors in E6/E7 transgenic mice [132]. Intravaginal immunization with live 
attenuated Salmonella enterica serovar Typhimurium expressing HPV-16 antigens induced transient 
inflammatory responses in the genital mucosa and conferred protection against subcutaneously 
implanted HPV-16 tumors [133].  
Clinical Models. The first clinical Listeria-based vaccines, using HPV-16 E7 antigen fused to a 
fragment of LLO, was found to be well tolerated and did not have any side effects in end-stage 
cervical cancer patients [134]. However, the trial was a non-controlled study and therefore no 
inference can be made regarding the differences in overall survival. Further data and trials need to be 
done to confirm the use of Listeria-based vaccines as an efficient vaccine for HPV infection. Although 
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a promising candidate for many cancer vaccines, Salmonella has yet to enter clinical trials for 
therapeutic HPV vaccine. 
4.1.2. Viral Vectors 
Many recombinant viral vectors (such as adenoviruses, fowlpox viruses, vaccinia viruses, vesicular 
stomatitis viruses and alphaviruses) have been used for therapeutic HPV vaccine development due to 
their high infection efficiency and expression of antigens in the infected cells (reviewed in [135]).  
Preclinical models. A replication-deficient adenovirus encoding fusion proteins comprised of 
calreticulin, known to enhance MHC-I expression on cell surface, and E7 antigen (CRT/E7) has been 
shown to generate a potent and protective cellular response to E7, in an established tumour model in 
mice [136]. This study thus suggested a therapeutic potential for viral vector. 
Clinical Models. Vaccinia virus is another viral vector that has been tested in both preclinical and 
clinical trials [135]. Phase I/II clinical trials with recombinant vaccinia virus expressing HPV-16/-18 
E6/E7 fusion protein (TA-HPV) have been shown to induce therapeutic effects in patients with  
early- or late-stage cervical cancer, vaginal intraepithelial neoplasia (VAIN) [137] and VIN (reviewed  
in [135]. Furthermore depending on the dose and schedule, the antigen-specific immune responses in 
E6/E7 transgenic mice can be augmented by co-expression of IL-12 in a Semliki Forest virus (SFV), 
an alphavirus, suggesting that the viral vectors can be further modified to enhance their potency [138]. 
In a recent phase II clinical trial, subcutaneous injections of TG4001 vaccine, consisting of an 
attenuated recombinant vaccinia virus containing the sequence for modified HPV-16 E6 and E7, and 
human IL-2 gene, induced the regression of CIN2/3 lesions in seven of 10 patients [139]. A second 
phase II clinical trial of randomized vs placebo patients (with a sample size of 200 individuals) is 
currently ongoing for this vaccine. Vaccinia virus is therefore a promising vaccine candidate against 
HPV infection. Viral vaccines are moreover safer than DNA vaccines (that will be discussed later in 
Section 4.3), as they contain only a small fraction of pathogenic genes [135], and they are currently use 
in both preclinical models and clinical trials.  
4.2. Protein and Peptide-Based Vaccines 
Protein and peptide-based vaccines are the most popular form of HPV therapeutic vaccines. 
Vaccination with HPV antigenic peptides involves the uptake and presentation of the peptide antigen 
in association with MHC molecules by DC. The polymorphic nature of MHC molecules in genetically 
diverse populations makes it difficult to identify one immunogenic epitope which would cover all 
individuals. However, the use of overlapping, long peptide vaccines based on HPV E6/E7 antigens has 
been effective in generating antigen-specific T-cell responses. This limited use of peptides is reduced 
when the entire protein is used. Since protein antigens can be processed by the patient’s DC, which 
contain the relevant human leukocyte antigens (HLA), vaccines based on protein antigens can evade 
the limitation of MHC specificity associated with peptide vaccines. Adjuvants and fusion with 
immunostimulatory molecules, such as IL-2, are often used to overcome poor immunogenicity 
associated with protein and peptide-based vaccines. Several protein and peptide vaccines against HPV 
E6 and/or E7 have been successfully tested in preclinical and clinical models. 
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Preclinical models. In a E7-expressing TC-1 tumor model, mice were vaccinated subcutaneously 
with HPV-16 E7 peptide, together with a pan HLA-DR epitope (PADRE) peptide and the TLR3 ligand 
poly(I:C) adjuvant. PADRE peptide and poly (I:C) were used to enhance the activation of CD4+ T 
helper cells and dendritic cells, respectively, which altogether generated anti-tumor effects against TC-1. 
This therapeutic effect was further enhanced when the vaccine was administered in the tumour mass 
itself, generating higher frequency of E7-specific CD8+ T-cells and leading to a better survival [140].  
Like peptides, proteins have been tested as candidates for therapeutic HPV vaccines. To enhance 
the efficacy of HPV protein-based vaccines, adjuvants such as liposome-polycationic–DNA (LPD) [141] 
and saponin-based adjuvant [142] have been successfully used in the mouse models. Similarly, fusion 
of HPV-16 E7 protein with Bordetella pertusis adenylyl cyclase (CyaA), which targets proteins to 
APC [143], or with Pseudomonas aeruginosa exotoxin A, which facilitates their translocation to 
enhance MHC class I presentation [144], have led to improved CTL responses.  
Clinical models. Several trials have demonstrated the successful use of peptide/protein based 
vaccines against HPV. A phase I trial involving overlapping HPV-16 E6 and E7 peptides with 
Montanide ISA51 adjuvant in end-stage cervical cancer patients and VIN grade III patients elicited 
broad IFN- associated T-cell responses [145]. In a similar study, vaccination with long synthetic 
peptides of E6 and E7 of HPV-16 was effective in the majority (79%) of grade 3 VIN patients [37]. 
Regarding protein-based vaccines, a HPV fusion protein composed of HPV-6 L2 and E7 (TA-GW) has 
been shown to be effective in generating antigen-specific T-cell responses in 24 patients with genital 
warts [146]. A formulation of a vaccine with ISCOMATRIX adjuvant and the HPV-16 E6/E7 fusion 
protein significantly enhanced E6 and E7-specific CD8+ T cell responses in patients compared with 
placebo controls [142,147]. Another fusion protein vaccine formulation with of HPV-16 E7 and 
Mycobacteria bovis derived heat shock protein (HSP), known to enhance CTL responses, was used in 
patients with high-grade anal intraepithelial neoplasia (AIN) [148] and showed clinical responses in  
13 out of 38 CIN3 patients [149]. Finally one other successful example is the TA-CIN vaccine (Tissue 
Antigen - Cervical Intraepithelial Neoplasia), which is a fusion of HPV16 viral proteins L2, E6 and 
E7. This vaccine is under license from Xenova Research Ltd. (Cambridge, UK) for the treatment of 
HPV16-associated genital diseases. A recent phase II trial investigating the use of imiquimod/TA-CIN 
vaccine in patients with VIN demonstrated significant infiltration of CD4 and CD8 T-cells, and 
complete lesion regression in 63% of patients [123]. The use of peptide/protein-based vaccine against 
HPV have been shown to be well-tolerated by patients, safe, with no obvious signs of toxicity other than 
a few flu-like syndromes. They overall have a good immunogenicity and have lead to successful results. 
4.3. Nucleic Acid-Based Vaccines 
4.3.1. DNA Vaccines  
DNA-based vaccines are another candidate for HPV-vaccine. They have been extensively studied in 
preclinical models, in order to optimize the cell targeting, DNA uptake and processing, presentation to 
MHC molecules... 
Preclinical models. Strategies to deliver DNA directly into DC may vary. The strategy using Gene 
gun can efficiently deliver DNA to Langerhans cells in the epidermis, which then express the antigens, 
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become mature and migrate to the draining lymph nodes, where they prime naïve T cells. This method 
has been shown to elicit HPV antigen-specific T cell immunity and antibody responses [150]. 
As with protein-based vaccines, DNA encoding HPV antigens are fused with molecules such as 
FMS-like tyrosine kinase 3 (flt3) ligands [151] and HSP [152] that are capable of targeting the 
antigens to the DC. Furthermore, DNA construct encoding a fusion protein that links antigenic peptide 
to MHC class I and 2-microglobulin [153] have been made to enhance antigen presentation by MHC 
class I molecules. In the similar fashion, DNA construct encoding a fusion protein that links antigenic 
peptide to a signal peptide for the endoplasmic reticulum and sorting signal for transmembrane 
proteins [154] have been made to enhance antigen presentation by MHC class II molecules.  
In a recent study, a DNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D 
genetically fused to human HPV-16 oncoproteins E5, E6, and E7, induced antigen-specific CD8+  
T-cell responses and conferred preventive resistance to transplantable murine TC-1 tumor cells [155]. 
Co-administration of DNA vectors encoding a co-stimulatory signal, such as GM-CSF or IL-12, has 
been shown to enhance the therapeutic antitumor effects [155].  
In another study, a DNA vaccine encoding calreticulin (CRT) linked to human HPV-16 E7 
(CRT/E7) showed increased intercellular uptake and processing of the DNA. With the TLR7 agonist 
Imiquimod, this vaccine generated E7-specific antitumor effects and prolonged the survival in treated 
mice, probably by also decreasing the number of myeloid-derived suppressor cells (MDSC) in the 
tumor microenvironment of tumor-bearing mice [71]. This CRT/E7 vaccine efficiency can be 
increased by the co-administration of a demethylating agent, 5-aza 2 deoxycytidine (DAC). This 
treatment decreases the methylation of the DNA and thus inhibit its gene silencing [156]. 
Clinical models. Several DNA vaccines have been tested in clinical trials for CIN2/3 patients 
(reviewed in [135]). A recent phase-I trial using HPV-16 E7 DNA linked with M. tuberculosis HSP70 
was tested in CIN2/3 patients. Fifteen CIN2/3 patients were given three different doses of vaccine  
(three each at 0.5 mg and 1 mg, nine at 3 mg). The vaccine led to complete regression of the lesions in 
three of nine patients treated with highest dose of the vaccine. E7-specific CD8+ T cell responses were 
detected in patients treated with vaccine at 1 mg and 3 mg [135,157].  
DNA-based vaccines are stable and easy to produce. They can lead to sustained cellular antigen 
expression compared to protein-based vaccines, which makes them a strong candidate for therapeutic 
HPV vaccines. However, they have limited potency to invoke innate defence mechanism because of 
lack of intrinsic ability to amplify and spread in vivo. Their use has been shown to be well-tolerated by 
patients, quite safe, and good immunogenes. Nevertheless, more studies are needed to further improve 
the efficiency, safety, and cost of potential DNA vaccines. 
4.3.2. RNA Vaccines 
RNA replicons are vaccines based on RNA viruses. They have the ability to self replicate in the 
infected host cell. Therefore, they can sustain the cellular antigen expression and as a result, can 
produce more antigenic protein than conventional DNA vaccines. However unlike DNA vaccines, 
RNA replicons cannot reproduce by themselves and therefore, can circumvent the possibility of 
integration into the host genome and cellular transformation. RNA replicons are customized to lack the 
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viral structural genes and thus, the vaccines may be repeatedly administrated in patients without the 
generation of neutralizing antibodies against viral capsid proteins.  
A DNA-launched RNA replicons vaccine, called “suicidal vaccine” has been made to increase the 
stability of RNA replicons. In this vaccine, suicidal DNA is transcribed into RNA replicons and cells 
uptaking the suicidal DNA vector eventually die due to apoptosis, thereby minimizing the concerns 
associated with potential integration of vaccine DNA into the host genome and cell transformation. 
However, the expression of inserted genes in these vectors is transient and it can shorten the functional 
lifespan of DC if DNA is targeted to DC, thereby reducing their effectiveness in stimulating the 
immune system. In one of the preclinical models, a suicidal DNA vector, pSCA1, encoding HPV-16 
E7 was fused with BCL-xL, an antiapoptotic protein, to enhance the survival of APC [158]. This 
vector generated higher E7-specific CD8+ cells and better anti-tumor immune responses than pSCA1 
DNA containing E7 gene alone [158]. In another study, vaccination of mice with DNA-launched KUN 
replicons, a flavivirus which does not induce apoptosis, encoding E7 epitopes generated CTL 
responses and protected mice against challenge with an E7-expressing epithelial tumor [159]. RNA 
replicons thus show promising results in preclinical models of HPV infection, but have not yet been 
investigated in clinical trials. 
4.4. Whole Cell Vaccines  
4.4.1. Tumor Cell-Based Vaccines 
Tumor cell-based vaccines have the advantage to cover a broad spectrum of tumor antigens. Tumor 
cells can be isolated from patients and manipulated to express immunostimulatory proteins such as IL-2, 
IL-12 and GM-CSF, ex vivo to enhance their immunogenicity (for review, see [160]). However, there 
is a potential concern of introducing new cancers to the patients.  
In a recent preclinical study in mice, forced expression in tumors of LIGHT, a ligand for the 
lymphotoxin-beta receptor, resulted in an increased expression of IFN- and chemoattractant cytokines 
such as IL-1, MIG, and MIP-2. This correlated with an increased frequency of tumor-infiltrating 
CD8+ T cells and eradication of large well-established tumors [161].  
These vaccines are mainly used when tumor antigens are not identified; however they may not be 
relevant in case of HPV as tumor antigens associated with HPV-infection are largely known and this 
could be the reason that these vaccines have not yet tested in clinical trials for HPV-associated cancers.  
4.4.2. Dendritic Cell-Based Vaccine 
DC vaccines are another way to enhance T-cell mediated immunity against HPV-associated lesions. 
Preclinical models. DC-based vaccines are the preferred choice for vaccine development and a 
number of methods have been used including the usage of different vectors, pulsing of DC with 
proteins and peptides or transfecting DC with DNA or RNA (see above and reviewed in [135]). In a 
TC-1 murine tumor model, vaccination with E7-presenting DC transfected with anti-apoptotic siRNA 
targeting Bim was shown to generate E7-specific CD8+ T cells and decrease tumor growth [162].  
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Clinical Models. In humans, autologous DCs were pulsed with HPV16 or HPV18 E7 recombinant 
proteins and E7-specific CD8+ T cell responses were observed in four out of 11 late stage cervical 
cancer patients [163]. In another clinical study, stage IB or IIA cervical cancer patients were 
vaccinated with autologous DC pulsed with recombinant HPV16/18 E7 antigens and keyhole limpet 
hemocyanin (KLH), an immunological carrier protein. This vaccine generated E7-specific T cell 
responses in 8 out of 10 patients and antibody responses in all patients [164]. 
DC vaccines are patient-specific, where clinicians harvest DC from the patient, load them  
with tumor antigens such as E6 or E7, and then inject these DC back into the patient, where they  
elicit antigen-specific potent antitumor immune response. The success of Provenge®, a DC vaccine 
incorporating prostatic acid phosphatase, in patients with advanced prostate cancer has generated 
strong interest for DC-based vaccines [165,166]. However, DC-based vaccines have serious 
limitations. Since these vaccines cannot be produced at a large scale, they are labour intensive and 
expensive. Nevertheless, DC-based vaccines have been tested in patients with HPV-associated cervical 
cancer by successfully transducing genes coding for E6 and E7 into DC.  
4.5. Combinational Approaches 
In Section 4 we discussed the different formulations that can potentially been used to create a 
therapeutic vaccine. In the examples we cited, some of the studies already used combinational 
approaches, by adding an adjuvant or a co-stimulatory signal to the vaccine itself. In this paragraph, 
we just want to highlight it a bit more.  
Prime-boost vaccination strategies use several of the available therapeutic vaccines in combination 
to induce higher levels of tumor specific immune response. Some of these have been evaluated in 
clinical trials for therapeutic HPV vaccines. In one trial, nine patients developed HPV16 specific T cell 
responses and three out of 10 patients showed a significant reduction in the size of the lesion, when 
high grade VIN were primed with TA-HPV and boosted with TA-CIN [137].  
Therapeutic HPV vaccines may potentially be combined with other therapeutic methods such as 
radiotherapy and chemotherapy to enhance the clinical outcome. In an experimental model, treatment 
with low-dose radiotherapy made the TC-1 tumor cells more susceptible to lysis by E7-specific CD8+ T 
cells, and enhanced antitumor effects in tumor bearing mice [167]. In a similar fashion, combination of 
5,6-dimethylxanthenone-4-acetic acid (DMXAA), a vascular disrupting agent, and treatment with E7 DNA 
vaccination generated potent antitumor immune responses in the splenocytes of tumor bearing mice [168].  
Therapeutic HPV vaccines may also be combined to co-stimulatory signal delivery or cytokine 
adjuvantizing. The use of CTLA-4 antibodies has been shown to be effective in murine TC-1 tumor 
models [169]. More recently, peritumoral administration of IL-12-producing tumor vaccines enhanced 
the effect of the cytostatic chemotherapeutic agent, gemcitabine, which was correlated with high 
production of IFN- by splenocytes [170].  
Another strategy to improve HPV-vaccine is to combine them with the depletion of regulatory cells 
such as Treg, MDSC, or NKT cells, as discussed in Section 2. However in a recent study, depletion of 
Treg did not enhance the immune response induced by SFV-based HPVE6/E7 vaccine against murine 
tumors, suggesting that the SFVeE6/7 vaccine may not require additional immune interventions [171]. 
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Thus, as it has already been described in many other cancer types, combinational approaches might 
be the gold strategies to generate a successful anti-HPV therapeutic vaccine. 
5. HPV Immunotherapy, the Future 
Although preventive HPV vaccines are now available to use, the high prevalence of HPV-associated 
malignancies worldwide suggests a potential benefit from developing therapeutic HPV vaccines. New 
leads, news targets and new research axis have to be investigated to maximize the chances to find a 
way towards therapeutic vaccines. 
5.1. Future Challenges and Resources? 
The HPV-derived VLP obtained by the self assembly of the viral L1 capsid protein have been 
generated in yeast and insect cell lines. However, the development of contained plant systems (i.e., plant 
cell suspension, hairy root cultures, microalgae, etc) provides a powerful alternative for the production of 
recombinant therapeutic molecules, such as IgG, IL-12 or IFNs. Plant cell suspension can be derived 
from tobacco, rice, soybean, tomato, alfalfa and carrot plants; hairy root cultures are generated from 
the interaction between Agrobacterium rhizogenes, a Gram-negative soil bacterium, and a host plant; 
and microalgae are photosynthetic heterotrophic microorganisms found in wet environments [172].  
The advantages offered by these systems are firstly their low-cost production, the safety of their 
production, their ability to generate post-translational modifications and to synthesize folded or 
assembled protein multimeres correctly, as well as alleviating ethical issues in generating high-grade 
pharmaceuticals. On the other hand, some parameters still need to be improved, as the protein yield is 
quite low (0.01–0.2 g/L) compared to mammalian or eukaryotic systems (1–3 g/L or 0.5–5 g/L, 
respectively), and also some post-translational modifications need to be adapted [173]. 
There is recent evidence of the successful usage of plant-produced pharmaceuticals by Biolex 
Therapeutics (www.biolex.com). The results of this phase II clinical trial for the treatment of patients 
with chronic hepatitis C with Locteron, an alpha-IFN produced in duckweed, were published in March 
2011 [174]. In relation to vaccine development, the very first veterinary vaccine derived from tobacco 
cell culture has been engineered by Dow AgroSciences (http://www.dowagro.com/), obtaining US 
Department of Agriculture (USDA) approval in 2006. Although not yet available commercially, this 
novel product represents the first approval for a plant-derived vaccine. 
5.2. Conclusions  
A successful HPV therapeutic vaccine should deal with both arms of the innate and adaptive 
immunity. The ideal vaccine should therefore generate high numbers of efficient tumor-specific and 
cytotoxic effector T-cells and promote inflammation. Together, this would prevent persistent HPV 
infection from progressing towards cervical cancer or even eradicate HPV. Moreover, within the tumor 
microenvironment and as already proven in other cancers, there are many cells and factors that may 
inhibit T-cell effector function and hinder the success of effective immunotherapy, such as Treg cells 
and immunosuppressive cytokines such as IL-10 and TGF-. Similarly, IFN- released by iNKT cells 
has shown to be immunosuppressive in the E7-expressing skin. Therefore, the transient depletion of 
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Treg, the blocking of IL-10 and TGF-β, the fine control of NKT-derived IFN-γ in the tumor 
microenvironment may enhance therapeutic HPV vaccine potency. More studies and knowledge are 
required to determine the role of those cells, as well as MSDC, mast cells and macrophages and other 
regulatory components of the innate immune system, that compose the tumor microenvironment and 
could play a role in HPV-associated cancers (summarized in Figure 2).  
Figure 2. Therapeutic strategies against HPV-infected lesions. The tumor microenvironment 
is composed of cells of the adaptive immune system (such as CD4 and CD8 T-cells, Treg) 
and cells of the innate immune system (such as DC, NKT, macrophages) and potentially 
other cells (Mast cells? MSDCs?) that could have a role in the response to HPV. Soluble 
factors including regulatory cytokines IL-10, TGF-β or IFN-γ may also be involved. This 
figure provides an overview of the different strategies that can be employed to generate 
therapeutic effects against HPV-infected epithelial lesions, which include live vector 
(viral/bacterial), protein or peptide, or nucleic acid (DNA/RNA) or VLP, together with the 
use of adjuvants such as TLR agonists or cytokines. Overall, the ideal vaccine would 
activate effector killer T-cells while silencing regulatory factors. The generation of 
memory cells that can mount a faster and stronger immune response would prevent 
reinfection by HPV and cancer relapse (inset). 
 
Cancers 2011, 3                         
 
3482
A potent therapeutic vaccine will most likely require the combination of current delivery systems 
(VLP, live vector, protein and DNA/RNA, plant-derived pharmaceuticals) associated with conventional 
therapeutic approaches (chemotherapy/radiotherapy, targeted depletion). With the increasing discovery 
of new drugs, development of new adjuvants, and the better understanding of tumor biology, we will 
have more opportunities to develop improved therapeutics against HPV-associated cancers. Successful 
clinical trials for therapeutic HPV vaccines based on positive preclinical data have now been  
published [37,123], and show that curing HPV-associated lesions is feasible.  
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